Kailera Therapeutics to Participate in September Investor Conferences

Kailera schedules two September 2026 investor webcasts as it advances multiple GLP-1–based obesity drug candidates through clinical development.

Rhea-AI Summary

Kailera Therapeutics (Nasdaq: KLRA) will participate in two investor conferences in September 2026 focused on healthcare and cardiometabolic disease.

The company will join a fireside chat at the Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Wednesday, September 23, 2026, at 9:40 a.m. ET. Kailera will also host a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 11:30 a.m. ET. Live webcasts of both events will be available on the Events page of Kailera’s investor website.

Key Terms

glp-1, gip, dual agonist, tri-agonist

4 terms

glp-1 medical

"multiple GLP-1-based mechanisms of action"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

gip medical

"GLP-1/GIP receptor dual agonist"

GIP commonly stands for Global Infrastructure Partners, a private investment firm that buys and manages large physical assets such as airports, power plants, toll roads and pipelines. Investors pay attention because when GIP acquires, invests in, or sells such assets it can alter cash flow, debt levels and long-term plans for those businesses—like a new landlord changing rents or making upgrades—affecting revenue, dividends and risk for shareholders and creditors.

dual agonist medical

"GLP-1/GIP receptor dual agonist"

A dual agonist is a single drug designed to activate two different biological targets or pathways at once, like one key that turns two locks to produce a combined effect. For investors, dual agonists can mean the potential for stronger or broader therapeutic benefits and larger market opportunities, but they also carry added development and regulatory risk because safety and effectiveness must be demonstrated for both actions together.

tri-agonist medical

"GLP-1/GIP/glucagon receptor tri-agonist"

A tri-agonist is a therapeutic molecule designed to activate three different biological targets or receptors at once, like a multitool that operates three switches with a single action. For investors, that matters because combining multiple mechanisms can increase the chance of stronger clinical effects or broader patient benefits, but it also adds scientific and regulatory complexity, development risk, and potential side-effect concerns compared with single-target drugs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences:

• Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum
  Wednesday, September 23, 2026, 9:40 a.m. ET
  Fireside Chat with Jamie Coleman, Chief Commercial Officer

• Stifel 2026 Virtual Cardiometabolic Forum
  Wednesday, September 30, 2026, 11:30 a.m. ET
  Fireside Chat with Ron Renaud, Chief Executive Officer, Doug Pagán, Chief Financial Officer, and Scott Wasserman, Chief Medical Officer

The live webcasts will be available on the Events page of Kailera’s investor website. A replay of the conference webcasts will be archived on the company's website for 90 days.

About Kailera Therapeutics 
Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," “suggest,” "plan," “goal,” “vision,” "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Contact Information
Maura Gavaghan 
Vice President, Investor Relations 
maura.gavaghan@kailera.com

Anna Robinson
Vice President, Communications
anna.robinson@kailera.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors access Kailera Therapeutics’ September 2026 conference appearances?

Live webcasts of Kailera’s fireside chats at the Bernstein Healthcare Forum and the Stifel 2026 Virtual Cardiometabolic Forum will be available on the Events page of the company’s investor website. A replay of the conference webcasts will be archived on the company’s website for 90 days.